Atlas Trials

A Study of the Early Activity of Ixekizumab (LY2439821) in Moderate-to-Severe Psoriasis

Clinical trial NCT02387801 · COMPLETED

Trial details

NCT number
NCT02387801
Sponsor
Eli Lilly and Company
Status
COMPLETED
Phase
Phase 3
Study type
INTERVENTIONAL
Psoriasis
Start date
2015-04-01
Primary completion
2015-09-01
Enrollment
12

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.